8-K: Senseonics Reports Strong Q4, Full-Year 2025 Revenue Growth

Senseonics Holdings, Inc. announced robust fourth quarter and full year 2025 financial results, driven by significant revenue growth and strategic commercialization efforts.

Summary

• Fourth quarter 2025 revenue increased 72% year-over-year to $14.3 million.
• Full year 2025 revenue grew 57% year-over-year to $35.3 million.
• U.S. new patient growth reached 103% in 2025 compared to 2024, largely due to direct-to-consumer marketing.
• Received CE Mark approval for Eversense 365, enabling commercialization in the European Union.
• Launched the first Eversense 365 Automated Insulin Delivery (AID) system integration with twiist in the U.S.
• Secured FDA Investigational Device Exemption (IDE) approval and enrolled the first patients in a pivotal trial for the self-powered Gemini sensor, expected to complete in the second half of 2026.
• Net loss for Q4 2025 was $20.8 million, and for full year 2025 was $69.1 million.
• Cash, cash equivalents, and investments stood at $94.3 million as of December 31, 2025.
• Forecasts full-year 2026 global net revenue to be approximately $58-$62 million, representing 65% to 76% year-over-year growth, with gross margins of approximately 50%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting strong revenue growth, successful commercialization efforts, and a clear strategic roadmap for 2026. The significant increase in SG&A expenses and continued net loss, while expected during a commercial transition, temper the overall sentiment slightly.

Positives

• Fourth quarter 2025 total revenue increased by 72% year-over-year to $14.3 million.
• Full year 2025 total revenue increased by 57% year-over-year to $35.3 million.
• U.S. new patient growth was 103% in 2025 compared to 2024, driven by direct-to-consumer marketing efforts.
• The number of active prescribers in the HCP channel grew over 80% from 2024 to 2025.
• Received CE Mark approval for Eversense 365, enabling its commercialization in the European Union.
• Secured FDA IDE approval and commenced a pivotal trial for the self-powered Gemini sensor, enrolling the first patients.
• Launched the integration of Eversense 365 with the twiist Automated Insulin Delivery (AID) System across the U.S.
• Gross profit for Q4 2025 increased to $7.7 million from $4.0 million in Q4 2024, and for full year 2025 increased to $15.8 million from $0.5 million in 2024, due to favorable margins, lower fixed manufacturing costs, and one-time impacts like VAT recoveries.
• Research and development expenses decreased by $0.6 million in Q4 2025 to $8.8 million, and by $9.5 million for the full year 2025 to $31.6 million, primarily due to the completion of Eversense 365 clinical trials and development efforts.
• Net loss decreased by $9.5 million for the full year 2025 to $69.1 million compared to $78.6 million in 2024.

Negatives

• Net loss for the fourth quarter of 2025 increased by $5.3 million year-over-year to $20.8 million.
• Selling, general and administrative expenses increased significantly by $10.9 million in Q4 2025 to $19.8 million, and by $18.3 million for the full year 2025 to $52.5 million, primarily driven by direct-to-consumer campaign investments, increased sales commissions, and costs related to taking over commercialization.
• The company continues to operate at a net loss, with a full-year 2025 net loss of $69.1 million.
• Cash and cash equivalents decreased from $74.597 million as of December 31, 2024, to $40.234 million as of December 31, 2025.

Risks

• Uncertainties related to the transition of commercial responsibility for Eversense from Ascensia, including the negotiation, finalization, and execution of local purchase agreements in the European Union.
• Uncertainties in insurer, regulatory, and administrative processes and decisions.
• Uncertainties in the development and registration and roll-out of new technology and solutions.
• Uncertainties in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties.
• Uncertainties inherent in the ongoing commercialization and expansion of the Eversense product and Senseonics' and its partners' activities.
• Uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs.

Future Outlook

Senseonics projects full-year 2026 global net revenue to be between $58 million and $62 million, representing a year-over-year growth of 65% to 76%. Gross margins are expected to be approximately 50% for the full year. The company plans to expand Eversense 365 compatibility with Automated Insulin Delivery (AID) systems, launch in Europe, and complete the Gemini pivotal trial in the second half of 2026.

Management Comments

• "In 2025, we took strategic actions to set the Company up for long term growth."
• "Successfully bringing commercial operations in-house and investing heavily in DTC marketing, we built the foundations necessary to achieve the full potential of the worlds first and only year-long CGM."
• "We delivered encouraging commercial results last year, and expect this momentum to continue."
• "In 2026 we plan to expand Eversense 365 compatibility with AID systems, launch in Europe and complete the Gemini pivotal trial, an important milestone for our exciting innovation pipeline."
• "These efforts, coupled with improved margins, set Senseonics up for continued strong performance this year and beyond."

Industry Context

StockSavvy.ai notes that Senseonics' strategic decision to bring commercial operations in-house and invest heavily in direct-to-consumer marketing aligns with a broader trend in the medical device industry to gain greater control over product distribution and customer engagement. The integration of Eversense 365 with Automated Insulin Delivery (AID) systems positions the company to compete more effectively in the rapidly evolving continuous glucose monitoring (CGM) market, where interoperability and user convenience are becoming increasingly critical for patient adoption and market share.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, strategic market expansion, and positive future outlook, though continued net losses and increased expenses may cause short-term concern.
• Customers (People with Diabetes): Benefit from expanded availability of Eversense 365 in Europe, integration with AID systems, and the ongoing development of the next-generation Gemini sensor, offering more options for long-term glucose monitoring.
• Employees: Increased focus on in-house commercial operations and R&D suggests potential for job growth and strategic importance within the company.
• Healthcare Providers: Growth in the Eon Care inserter network and active prescribers indicates increased engagement and adoption of Eversense products within the medical community.

Next Steps

• Expand Eversense 365 compatibility with Automated Insulin Delivery (AID) systems.
• Launch Eversense 365 in Europe.
• Complete the Gemini pivotal trial in the second half of 2026.
• Continue the transition of Eversense commercialization from Ascensia and bring the entire sales and marketing infrastructure in-house.
• Hold a conference call on March 2, 2026, to discuss financial results and outlook.

Key Dates

Recommendation

The company demonstrates strong revenue growth and strategic execution, including successful commercialization efforts and product development milestones. The positive 2026 outlook and improved gross margins are encouraging. However, the significant increase in selling, general, and administrative expenses and continued net losses, while part of a strategic transition, warrant a 'hold' recommendation. Investors should monitor the execution of the commercial transition, the progress of the Gemini trial, and the path to profitability before considering a stronger position.

Keywords

Continuous Glucose Monitoring, CGM, Diabetes, Eversense, Senseonics, SENS, Medical Technology, Financial Results, Q4 2025, Full Year 2025, FDA Approval, CE Mark, AID System, Gemini Sensor